Farms.com Home   News

Average Prairie Chickpea Harvest Expected; Global Supplies Tight

At a time when worldwide supplies are tight, Western Canada appears headed toward an average chickpea harvest this year. 

Colin Young, manager of Mid-West Grain Ltd. in Moose Jaw, said there is considerable variability in the Prairie chickpeas crop, with just localized showers across the main production province of Saskatchewan following a widespread rain event back in about May. Some crops appear to have good production potential, while others are below, he said. 

Adding it all up, Young said he’s confident of an average crop. 

In its latest supply-demand estimates released July 20, Agriculture Canada forecast 2022 Canadian chickpea output at 110,000 tonnes, up 44% from last year’s drought-impacted crop. But at an estimated 305,000 tonnes, the total new-crop supply is nonetheless projected to fall from 376,000 the previous year due to a sharp reduction in carry-in stocks from the old-crop marketing year. And even with a decline in exports, 2022-23 ending stocks are still projected to decline, falling to 120,000 tonnes from 150,000

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.